AUTL
Autolus Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$375.26M
P/E Ratio
—
EPS
$-1.08
Beta
2.00
52W High
$2.70
52W Low
$1.15
50-Day MA
$1.51
200-Day MA
$1.62
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | $1.08M |
| Gross Profit (TTM) | $-26.48M |
| EBITDA | $-68.94M |
| Operating Margin | -6571.00% |
| Return on Equity | -29.60% |
| Return on Assets | -22.30% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $5.91 |
| Price-to-Book | 2.21 |
| Price-to-Sales (TTM) | 347.95 |
| EV/Revenue | 2.183 |
| EV/EBITDA | 0.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 83655.00% |
| Shares Outstanding | $266.14M |
| Float | $33.90M |
| % Insiders | 18.08% |
| % Institutions | 77.53% |
Historical Volatility
HV 10-Day
69.40%
HV 20-Day
60.50%
HV 30-Day
65.52%
HV 60-Day
64.82%
HV Rank
23.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($8.81 target)
1
Strong Buy10
BuyData last updated: 4/30/2026